Merrill Matthews, Ph.D., is a resident scholar with the Institute for Policy Innovation, a research-based, public policy “think tank.” He is a health policy expert and opinion contributor at The Hill. He also serves on the Texas Advisory Committee of the U.S. Commission on Civil Rights.
Dr. Matthews is a past president of the Health Economics Roundtable for the National Association for Business Economics, the largest trade association of business economists. Dr. Matthews also served for 10 years as the medical ethicist for the University of Texas Southwestern Medical Center’s Institutional Review Board for Human Experimentation, co-author of On the Edge: America Faces the Entitlements Cliff, and has contributed chapters to several books, including Physician Assisted Suicide: Expanding the Debate and The 21st Century Health Care Leader and Stop Paying the Crooks (on Medicare fraud).
He has been published in numerous journals and newspapers, including The Wall Street Journal, Investor’s Business Daily, Barron’s, USA Today, Forbes magazine and the Washington Times. He was an award-winning political analyst for the USA Radio Network.
Dr. Matthews received his Ph.D. in Humanities from the University of Texas at Dallas.
A step-in-the-right-direction budget—if the reality matches the rhetoric, which it often doesn't.
Democratic presidential candidates fly to campaign stops in private jets to scold the rest of us about our carbon footprint.
Most presidential candidates call for change. Sanders is much bolder; he’s calling for a “revolution.”
Being a disrupter could be either positive or negative, depending on whether and how a voter thinks the country needs disrupting.
Efforts to control prescription-drug prices by setting prices through a government mandate are not likely to control overall prescription-drug spending.
Governments can't act as quickly as private sector drug companies when it comes to finding a vaccine for the coronavirus or any other epidemic.
Advertising is a way companies convey important information to consumers about products that may help them. The return on investment isn't just to drug companies, it's to people who act on that important medical information.
President Trump and many in Congress want to reduce prescription drug prices. This paper discusses how drug prices are determined and explains why political efforts to reduce them would be both harmful and counterproductive.
At least some World Economic Forum attendees think we have reached "peak laissez-faire," meaning it's time to give government more control over our economies and our liberties.
One of the president's top trade advisors sees nothing but positives from imposing tariffs. A more balanced view sees some positives, but many negatives.